Randomized Trial Evaluating LND101 Fecal Microbiota Transplant with Immune Checkpoint Blockade in Advanced Melanoma
Led by Canadian Cancer Trials Group · Updated on 2026-09-15
128
Participants Needed
15
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether adding a treatment called LND101 for Fecal Microbiota Transplant FMT to the usual immunotherapy treatment, Immune Checkpoint Blockade ICB, can reduce the chance of melanoma growing or spreading in people with advanced melanoma. The study compares this combination approach to the standard ICB treatment alone to see which is better for managing advanced melanoma. Immunotherapy aims to activate the immune system to fight the cancer, possibly slowing its growth or killing cancer cells.
Participants will be divided into two groups one receiving standard ICB treatment alone, and the other receiving a single dose of LND101 capsules taken by mouth after bowel preparation, followed by standard ICB treatment. Approximately 40 capsules containing processed fecal material are given 7 days before starting the ICB drugs. The choice of ICB drugs, which may be single agents or combinations, is made before participants join the study and remains the same throughout.
During the study, participants will be monitored regularly to assess how long they live without disease progression and overall survival over four years. Researchers will also measure tumor response rates and track the number and severity of any side effects. Participants will provide blood and stool samples for analysis and tumor tissue if available. The study requires participants to have measurable disease and be able to take capsules. Follow-up will continue through the study duration to collect safety and effectiveness information.
CONDITIONS
Brief Title
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
Research Team
J
Janet Dancey
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Solid organ transplant recipients or planned recipients
Living with HIV
Active infection requiring antibiotics without 2-week washout
Pregnancy, breastfeeding, or planning to conceive/father children during the trial
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 4 years
Participants receive either standard immune checkpoint blockade treatment alone or a combination of LND101 fecal microbiota transplant and immune checkpoint blockade.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 12a Study of Intratumoral T3011 Alone and with Intravenous Pembrolizumab for Advanced or Metastatic Solid Tumors
Exploratory Study of LM103 Injection with TIL Transfer for Advanced Solid Tumors Including Melanoma, Lung, and Cervical Cancer
Study of Tetanus Diptheria or Polio Booster Vaccines to Improve Immune Checkpoint Therapy Response in Adults with Metastatic Melanoma
A Phase 12a Study of REGN10597 Alone or With Cemiplimab for Adults With Advanced Melanoma, Renal Cell Carcinoma, or Other Solid Tumors
Phase 1 Study of NM1F Alone and With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Metastatic Melanoma Treatment Trial Using Tumor-Infiltrating Lymphocytes and IL-2 With or Without Pembrolizumab
Phase III Study of Vemurafenib and Metformin for Unresectable Stage IIIC and IV BRAF V600E Positive Melanoma
Phase III Study of NUC-7738 Alone and with Pembrolizumab in Adults with Advanced Solid Tumors, Melanoma, and Lymphoma
Study to Collect Blood and Tissue Samples from People With Malignant Melanoma and Healthy Volunteers
To Understand Melanoma and Discover New Ways to Diagnose and Treat It
Dose Finding and Expansion Trial of BI 3810944 in Adults With Advanced Solid Tumours and Melanoma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial.
Danial Khan Hadi, Kelly J Baines, Behnam Jabbarizadeh...